LLY

768.15

+2.94%↑

JNJ

176.55

-0.3%↓

ABBV

216.89

+0.98%↑

UNH

341.7

-2.13%↓

AZN

77.95

+0.22%↑

LLY

768.15

+2.94%↑

JNJ

176.55

-0.3%↓

ABBV

216.89

+0.98%↑

UNH

341.7

-2.13%↓

AZN

77.95

+0.22%↑

LLY

768.15

+2.94%↑

JNJ

176.55

-0.3%↓

ABBV

216.89

+0.98%↑

UNH

341.7

-2.13%↓

AZN

77.95

+0.22%↑

LLY

768.15

+2.94%↑

JNJ

176.55

-0.3%↓

ABBV

216.89

+0.98%↑

UNH

341.7

-2.13%↓

AZN

77.95

+0.22%↑

LLY

768.15

+2.94%↑

JNJ

176.55

-0.3%↓

ABBV

216.89

+0.98%↑

UNH

341.7

-2.13%↓

AZN

77.95

+0.22%↑

Search

TG Therapeutics Inc

Ouvert

SecteurSoins de santé

31.63 0.57

Résumé

Variation du prix de l'action

24h

Actuel

Min

31.23

Max

31.89

Chiffres clés

By Trading Economics

Revenu

23M

28M

Ventes

20M

141M

P/E

Moyenne du Secteur

85.211

35.664

Marge bénéficiaire

19.97

Employés

370

EBITDA

25M

38M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+1.59% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

578M

5.1B

Ouverture précédente

31.06

Clôture précédente

31.63

Sentiment de l'Actualité

By Acuity

21%

79%

48 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

TG Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 sept. 2025, 22:39 UTC

Acquisitions, Fusions, Rachats

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept. 2025, 16:43 UTC

Principaux Mouvements du Marché

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept. 2025, 16:42 UTC

Principaux Mouvements du Marché

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept. 2025, 16:35 UTC

Principaux Mouvements du Marché

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Expects Commercial Launch in 2029

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept. 2025, 17:50 UTC

Acquisitions, Fusions, Rachats

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

Comparaison

Variation de prix

TG Therapeutics Inc prévision

Objectif de Prix

By TipRanks

1.59% hausse

Prévisions sur 12 Mois

Moyen 32.67 USD  1.59%

Haut 50 USD

Bas 11 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

1

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

N/A / 34.86Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

48 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat